Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
Maxwell Stefan, Yooli Kim Light, Jennifer L. Schwedler, Peter Mcilroy, Colleen M. Courtney, Edwin A. Saada, Christine E. Thatcher, Ashlee M. Phillips, Feliza Bourguet, Catherine M. Mageeney, Summer A. McCloy, Nicole M. Collette, Oscar Negrete, Joseph S. Schoeniger, Dina R. Weilhammer, Brooke Harmon
Abstract
H-huFc antibodies described herein represent viable candidates for further preclinical evaluation and another tool to add to our therapeutic arsenal to address the COVID-19 pandemic.
Topics & Concepts
VirologyAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralizing antibodyCoronavirusCoronavirus disease 2019 (COVID-19)Single-domain antibodyVirusPandemicBiologyComputational biologyMedicineImmunologyDiseaseInfectious disease (medical specialty)PathologyMonoclonal and Polyclonal Antibodies ResearchSARS-CoV-2 and COVID-19 ResearchBacteriophages and microbial interactions